Stay updated with breaking news from Processa Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price objective reduced by Oppenheimer from $5.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Processa Pharmaceuticals’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at […]
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for shares of Processa Pharmaceuticals in a research report issued on Monday, April 3rd. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.28) per share for the quarter, down […]
Operator: Greetings and welcome to the Processa Pharmaceuticals Year-End 2022 Earnings Call and Corporate Update. As a reminder, this call is being recorded.
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) is set to announce its earnings results after the market closes on Thursday, March 30th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Processa Pharmaceuticals Stock Performance Processa Pharmaceuticals stock opened at $0.48 on Friday. The firm has a market cap of $8.07 […]
Operator: Greetings, and welcome to Processa Pharmaceuticals third-quarter 2022 earnings call and corporate update. At this time, all participants are in a listen-only mode.